Management of antipsychotic side effects

Primary Psychiatry

Volumn 14, Issue 7, 2007, Pages 77-82

  Kaushik, Saurabh ^a   Lindenmayer, Jean Pierre ^a   Khan, Anzalee ^a  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

AGRANULOCYTOSIS; AKATHISIA; BLOOD PRESSURE; BREAST TENDERNESS; COGNITIVE DEFECT; COMA; CONFUSION; CREATINE KINASE BLOOD LEVEL; DELIRIUM; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIAPHORESIS; DRUG EFFICACY; DRUG TOLERABILITY; DYSARTHRIA; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HUMAN; HYPERPROLACTINEMIA; INCONTINENCE; JAUNDICE; LACTATION; LEUKOCYTOSIS; LEUKOPENIA; LIVER TOXICITY; MACROGLOSSIA; MENSTRUAL IRREGULARITY; MENTAL DISEASE; METABOLIC DISORDER; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OCULOGYRIC CRISIS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATIENT COMPLIANCE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUDDEN DEATH; TACHYCARDIA; TARDIVE DYSKINESIA; THROMBOCYTOPENIA; TORSADE DES POINTES; TORTICOLLIS; TREATMENT PLANNING; TREMOR; TRISMUS; WEIGHT GAIN;

EID: 34547379204     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63(12):1121-1128.
2. Stahl SM, The psychopharmacology of energy and fatigue. J Clin Psychiatry. 2002;63(1):7-8.
3. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl). 1996;124(1-2):2-34.
4. Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl). 2002;159(3):238-247.
5. Makela EH, Miller K, Cutlip WD. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry. 2003;64(4):485-486.
6. Dequardo JR. Modafinil-associated clozapine toxicity. Am J Psychiatry. 2002;159(7):1243-1244.
7. Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA. Is psychosis exacerbated by modafinil? Arch Gen Psychiatry. 2002;59(3):292-293.
8. Practice Guidelines for the Treatment of Patients With Schizophrenia. Washington, DC: American Psychiatric Association; 2000:86.
9. Diagnostic and Statistical Manual of Mental Diorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
10. Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. Antipsychotic drugs: is more worse? A metaanalysis of the published randomized control trials. Psychol Med. 1994;24(2):307-316.
11. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59(2):69-75.
12. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry. 2002;14(1):47-57.
13. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2002;(1):CD001950.
14. Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006;(4):CD003727.
15. Kramer MS, Gorkin RA, DiJohnson C, Sheves P Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study. Biol Psychiatry. 1988;24(7):823-827.
16. Adler L, Angrist B, Peselow E, Corwin J, Maslansky R, Rotrosen J. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry. 1986;149:42-45.
17. Kane JM, Marder SR. Schizophrenia and other psychotic disorders. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1471.
18. Janicak PG. The CATIE study and its implications for antipsychotic drug use. Essent Psychopharmacol. 2006;7(1):53-63.
19. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000;22(1):73-81.
20. Lieberman JA, Tasman A. Antipsychotic drugs. In: Lieberman JA, Tasman A. Handbook of Psychiatric Drugs. John Wiley & Sons; 2006:26.
21. Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry. 1998;44(6):378-381.
22. Francis J, Eubanks JH, Mclntyre Burnham W. Diazepam-potentiated [3H]phenytoin binding is associated with peripheral-type benzodiazepine receptors and not with voltage-dependent sodium channels. Brain Res. 2000;876(1-2):131-140.
23. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85(1):129-135.
24. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry. 1989;50(8):295-298. Erratum in: J Clin Psychiatry. 1989;50(12):472.
25. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
26. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136(3):317-320.
27. Lieberman JA, Alvir J, Mukherjee S, Kane JM. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch Gen Psychiatry. 1989;46(10):908-913.
28. Louza MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years' follow-up. J Clin Psychopharmacol. 2005;25(2):180-182.
29. Barak Y, Swartz M, Shamir E, Stein D, Weizman A. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry. 1998;10(3):101-105.
30. Priam DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother. 2005;39(12):2065-2072.
31. Dorevitch A, Lerner V, Shalfman M, Kalian M. Lack of effect of vitamin E on serum creatine phosphokinase in patients with long-term tardive dyskinesia. Int Clin Psychopharmacol. 1997;12131:171-173.
32. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56(9):836-841.
33. Miller ER, Pastor-Barriuso R, Dalai D, Riemersma RA, Appel U, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37-46.
34. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279-1281.
35. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193-197.
36. Cole JO, Davis JM. Antipsychotic drugs. In: Bellak L, Loeb L, eds. The Schizophrenic Syndrome. New York, NY: Grune & Stratton; 1969:478-568.
37. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(suppl 18):47-56.
38. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686- 1696.
39. Lader M. Some adverse effects of antipsychotics: prevention and treatment. J Clin Psychiatry. 1999;60(suppl 12):18-21.
40. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry. 2001;62(suppl 23):5-12.
41. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62(suppl 7):32-37.
42. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32.
43. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
44. Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005;162(5):954-962.
45. Henderson DC, Fan X, Copeland PM, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand. 2007;115(2):101-105.
46. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand. 2006;113(2):142-147.
47. Birt J. Management of weight gain associated with antipsychotics. Ann Clin Psychiatry. 2003;15(1):49-58.
48. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002;159(4):655-657.
49. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006;163(12):2072-2079.
50. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry. 1999;156(9):1471.
51. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24(3):381-390.
52. Al-Khatib SM, Allen LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120-2127. Erratum in: JAMA. 2003;290(10):1318.
53. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. 2003;107(2):85-95.
54. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158(11):1774-1782.
55. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546. Erratum in: J Clin Psychiatry. 1998;59(4):200.
56. Perkins DO. Prolactin and endocrine related disorders. In: Meyer JM, Nasrallah HA, eds. Medical Illness in Schizophrenia. Arlington, VA: American Psychiatric Publishing; 2003:215-232.
57. Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002;302(3):1129-1134.
58. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med. 1992;22(4):305-327.
59. Correa N, Opler LA, Kay SR, Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychopharmacol. 1987;7(2):91-95.
60. Kane JM, Lieberman JA. Adverse Effects of Psychotropic Drugs. New York, NY: Guilford Press; 1992.
61. Clozaril [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2003.
62. Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci. 1994;6(3).-250-256.
63. Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry. 1994;55(suppl B):153-156.
64. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol. 2001;39(1):1-14.
65. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and Practice of Psychopharmacotherapy. Baltimore, MD: Williams & Wilkins; 1993.